Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Agappe Diagnostics Of India Expects 300 Percent Growth This Year

This article was originally published in PharmAsia News

Executive Summary

India's Agappe Diagnostics says it expects a 300 percent growth over the rest of this year, three times the percentage growth of the previous year. Agappe attributed the expected gains to an appreciating euro and high prices in Western countries. Agappe's managing director, Thomas John, said his firm expects to acquire technology to help it take advantage of India's lower manufacturing costs. John said the past year's situation of an appreciating euro and high Western production costs caused problems in reducing prices, but the technology aspect was expected to be an offset. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel